-
Something wrong with this record ?
Aprotinin reduces the procalcitonin rise associated with complex cardiac surgery and cardiopulmonary bypass
P. Maruna, AA. Klein, J. Kunstýř, KM. Plocová, F. Mlejnský, J. Lindner
Language English Country Czech Republic
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT11210
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Aprotinin therapeutic use MeSH
- Biomarkers blood MeSH
- Time Factors MeSH
- Endarterectomy * MeSH
- Hemostatics therapeutic use MeSH
- Interleukin-1beta blood MeSH
- Interleukin-6 blood MeSH
- Interleukin-8 blood MeSH
- Calcitonin blood MeSH
- Cardiac Surgical Procedures * MeSH
- Cardiopulmonary Bypass * MeSH
- Tranexamic Acid therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Inflammation Mediators blood MeSH
- Pulmonary Embolism blood complications surgery MeSH
- Hypertension, Pulmonary blood etiology surgery MeSH
- Protein Precursors blood MeSH
- Aged MeSH
- Tumor Necrosis Factor-alpha blood MeSH
- Up-Regulation MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Aprotinin, a nonspecific serine protease inhibitor, has been primarily used as a haemostatic drug in cardiac surgery with cardio-pulmonary bypass (CPB). This study investigated the effect of aprotinin on the post-operative levels of procalcitonin (PCT) and a set of cytokines in patients undergoing pulmonary artery endarterectomy (PEA). We analyzed 60 patients with chronic thromboembolic pulmonary hypertension undergoing PEA. 30 patients (Group A) were treated with aprotinin (2,00,00 IU prior anesthesia, then 2,00,00 IU in CPB prime and 50,00 IU per hour continuously); a further 30 patients (Group B) received tranexamic Acid (1 g before anesthesia, 1 g after full heparin dose and 2 g in CPB prime). PCT, TNFalpha, IL-1beta, IL-6, and IL-8 arterial concentrations were measured from before until 72 hours after surgery. Aprotinin significantly affected early post-PEA plasma PCT. Patients treated with aprotinin (Group A) had lower peak PCT levels compared to patients in Group B (1.52 ng/ml versus 2.18, p=0.024). Postoperative peak values of PCT and IL-6 correlated closely in both groups (r=0.78, r=0.83 respectively). Aprotinin attenuates the post-PEA increase of PCT in the same manner as other pro-inflammatory cytokines. Significant correlation between PCT and IL-6 post-surgery may be indicative of an indirect IL-6-mediated pathway of PCT alteration.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13033370
- 003
- CZ-PrNML
- 005
- 20150113141210.0
- 007
- ta
- 008
- 131015s2013 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.932375 $2 doi
- 035 __
- $a (PubMed)23173677
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Maruna, Pavel, $u Institute of Pathological Physiology of the First Faculty of Medicine, Charles University, Prague, Czech Republic. maruna@lf1.cuni.cz $d 1965- $7 xx0000273
- 245 10
- $a Aprotinin reduces the procalcitonin rise associated with complex cardiac surgery and cardiopulmonary bypass / $c P. Maruna, AA. Klein, J. Kunstýř, KM. Plocová, F. Mlejnský, J. Lindner
- 520 9_
- $a Aprotinin, a nonspecific serine protease inhibitor, has been primarily used as a haemostatic drug in cardiac surgery with cardio-pulmonary bypass (CPB). This study investigated the effect of aprotinin on the post-operative levels of procalcitonin (PCT) and a set of cytokines in patients undergoing pulmonary artery endarterectomy (PEA). We analyzed 60 patients with chronic thromboembolic pulmonary hypertension undergoing PEA. 30 patients (Group A) were treated with aprotinin (2,00,00 IU prior anesthesia, then 2,00,00 IU in CPB prime and 50,00 IU per hour continuously); a further 30 patients (Group B) received tranexamic Acid (1 g before anesthesia, 1 g after full heparin dose and 2 g in CPB prime). PCT, TNFalpha, IL-1beta, IL-6, and IL-8 arterial concentrations were measured from before until 72 hours after surgery. Aprotinin significantly affected early post-PEA plasma PCT. Patients treated with aprotinin (Group A) had lower peak PCT levels compared to patients in Group B (1.52 ng/ml versus 2.18, p=0.024). Postoperative peak values of PCT and IL-6 correlated closely in both groups (r=0.78, r=0.83 respectively). Aprotinin attenuates the post-PEA increase of PCT in the same manner as other pro-inflammatory cytokines. Significant correlation between PCT and IL-6 post-surgery may be indicative of an indirect IL-6-mediated pathway of PCT alteration.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a aprotinin $x terapeutické užití $7 D007611
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a kalcitonin $x krev $7 D002116
- 650 12
- $a kardiochirurgické výkony $7 D006348
- 650 12
- $a kardiopulmonální bypass $7 D002315
- 650 12
- $a endarterektomie $7 D004691
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hemostatika $x terapeutické užití $7 D006490
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a plicní hypertenze $x krev $x etiologie $x chirurgie $7 D006976
- 650 _2
- $a mediátory zánětu $x krev $7 D018836
- 650 _2
- $a interleukin-1beta $x krev $7 D053583
- 650 _2
- $a interleukin-6 $x krev $7 D015850
- 650 _2
- $a interleukin-8 $x krev $7 D016209
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a proteinové prekurzory $x krev $7 D011498
- 650 _2
- $a plicní embolie $x krev $x komplikace $x chirurgie $7 D011655
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a kyselina tranexamová $x terapeutické užití $7 D014148
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a TNF-alfa $x krev $7 D014409
- 650 _2
- $a upregulace $7 D015854
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Klein, A. A. $u Department of Anesthesia, Papworth Hospital, Cambridge, United Kingdom
- 700 1_
- $a Kunstýř, Jan $u Department of Anesthesiology and Intensive Care, General Teaching Hospital and the First Faculty of Medicine, Charles University in Prague $7 xx0083634
- 700 1_
- $a Plocová, Kateřina M. $u Second Department of Cardiovascular Surgery, General Teaching Hospital and the First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 xx0171717
- 700 1_
- $a Mlejnský, František $u Second Department of Cardiovascular Surgery, General Teaching Hospital and the First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 _AN029069
- 700 1_
- $a Lindner, Jaroslav, $u Second Department of Cardiovascular Surgery, General Teaching Hospital and the First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $d 1957- $7 mzk2005269705
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 62, č. 1 (2013), s. 27-33
- 856 41
- $u http://www.biomed.cas.cz/physiolres/archive.htm $y domovská stránka časopisu - plný text volně přístupný = fulltext
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 3 $z 0
- 990 __
- $a 20131015 $b ABA008
- 991 __
- $a 20150113141351 $b ABA008
- 999 __
- $a ok $b bmc $g 999121 $s 831824
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 62 $c 1 $d 27-33 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- GRA __
- $a NT11210 $p MZ0
- LZP __
- $b NLK111 $a Pubmed-20131015
